What is the clinical evidence to support off-label rapamycin therapy in healthy adults?

Jacob M Hands, Michael S Lustgarten, Leigh A Frame, Bradley Rosen

The George Washington University School of Medicine and Health Sciences, Washington DC, DC 20037, USA.The George Washington University School of Medicine and Health Sciences, Washington DC, DC 20037, USA. · pubmed

Paper

Abstract

Low dose rapamycin therapy has been proposed as a longevity candidate in healthy aging adults. We present a review of the evidence for low dose rapamycin and rapalog therapies in healthy human adults and model the findings of one cohort study using the PhenoAge model. Despite the preclinical evidence supporting the use of sirolimus to enhance mean and maximal lifespan, the data in humans have yet to establish that rapamycin, or its analogues, is a proven seno-therapeutic that can delay aging in healthy older adults. Rapamycin and rapalogs warrant further study with larger cohorts to better establish their contribution to human aging.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper reviews the clinical evidence for low dose rapamycin as a potential therapy for healthy aging adults. The focus on rapamycin as a candidate for longevity interventions aligns with the goal of addressing the root causes of aging.

Author of this paper? Send a correction.